Eli Lilly And also Carbon monoxide’s LLY tirzepatide (10 mg and also 15 mg) accomplished exceptional weight management contrasted to sugar pill at 72 weeks of therapy in arise from SURMOUNT-2.
The research study satisfied both co-primary and also crucial additional purposes for tirzepatide contrasted to sugar pill for both estimands.
Mounjaro (tirzepatide) produced Q1 sales of $568.5 million.
Those taking tirzepatide shed approximately 15.7% (34.4 pound. or 15.6 kg) of body weight for the efficiency estimand.
The test reviewed 938 grown-up individuals with weight problems and also kind 2 diabetes mellitus.
Associated: Eli Lilly States Stock For Diabetes Mellitus Mounjaro Is Readily Available, Most Likely Finishing Scarcity
For the efficiency estimand, individuals taking tirzepatide accomplished ordinary weight decreases of 13.4% (29.8 pound. or 13.5 kg) on 10 mg and also 15.7% (34.4 pound. or 15.6 kg) on 15 mg contrasted to sugar pill (3.3%, 7.0 pound. or 3.2 kg).
Furthermore, 81.6% (10 mg) and also 86.4% (15 mg) of individuals taking tirzepatide accomplished a minimum of 5% body weight decrease, the various other co-primary endpoint, contrasted to 30.5% of those taking a sugar pill.
Tirzepatide additionally satisfied all crucial additional purposes, that included a decrease in A1C and also various other cardiometabolic specifications.
Lilly anticipates governing activity as very early as late 2023.
Rate Activity: LLY shares are up 2.26% at $384.79 on the last check Thursday.
